These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39322963)

  • 1. Sample size recalculation in three-stage clinical trials and its evaluation.
    Bokelmann B; Rauch G; Meis J; Kieser M; Herrmann C
    BMC Med Res Methodol; 2024 Sep; 24(1):214. PubMed ID: 39322963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoothing Corrections for Improving Sample Size Recalculation Rules in Adaptive Group Sequential Study Designs.
    Herrmann C; Rauch G
    Methods Inf Med; 2021 May; 60(1-02):1-8. PubMed ID: 33648007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation.
    Herrmann C; Pilz M; Kieser M; Rauch G
    Stat Med; 2020 Jul; 39(15):2067-2100. PubMed ID: 32249968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving sample size recalculation in adaptive clinical trials by resampling.
    Herrmann C; Kluge C; Pilz M; Kieser M; Rauch G
    Pharm Stat; 2021 Nov; 20(6):1035-1050. PubMed ID: 33792167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extension of a conditional performance score for sample size recalculation rules to the setting of binary endpoints.
    Bokelmann B; Rauch G; Meis J; Kieser M; Herrmann C
    BMC Med Res Methodol; 2024 Jan; 24(1):15. PubMed ID: 38243169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data.
    Harden M; Friede T
    Biom J; 2020 Sep; 62(5):1284-1299. PubMed ID: 32128868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
    Friede T; Kieser M
    Pharm Stat; 2011; 10(1):8-13. PubMed ID: 19943322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A variational approach to optimal two-stage designs.
    Pilz M; Kunzmann K; Herrmann C; Rauch G; Kieser M
    Stat Med; 2019 Sep; 38(21):4159-4171. PubMed ID: 31264243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials.
    Kunzmann K; Grayling MJ; Lee KM; Robertson DS; Rufibach K; Wason JMS
    Stat Med; 2022 Feb; 41(5):877-890. PubMed ID: 35023184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size recalculation in internal pilot study designs: a review.
    Friede T; Kieser M
    Biom J; 2006 Aug; 48(4):537-55. PubMed ID: 16972704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-stage designs for cross-over bioequivalence trials.
    Kieser M; Rauch G
    Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On sample size determination in multi-armed confirmatory adaptive designs.
    Wassmer G
    J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
    Liu Q; Li G; Anderson KM; Lim P
    J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size determination in group-sequential clinical trials with two co-primary endpoints.
    Asakura K; Hamasaki T; Sugimoto T; Hayashi K; Evans SR; Sozu T
    Stat Med; 2014 Jul; 33(17):2897-913. PubMed ID: 24676799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-stage group-sequential designs with delayed responses - what is the point of applying corresponding methods?
    Schüürhuis S; Wassmer G; Kieser M; Pahlke F; Kunz CU; Herrmann C
    BMC Med Res Methodol; 2024 Oct; 24(1):242. PubMed ID: 39420280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upstrapping to determine futility: predicting future outcomes nonparametrically from past data.
    Wild JL; Ginde AA; Lindsell CJ; Kaizer AM
    Trials; 2024 May; 25(1):312. PubMed ID: 38725072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal planning of adaptive two-stage designs.
    Pilz M; Kunzmann K; Herrmann C; Rauch G; Kieser M
    Stat Med; 2021 Jun; 40(13):3196-3213. PubMed ID: 33738842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining different phases in the development of medical treatments within a single trial.
    Bauer P; Kieser M
    Stat Med; 1999 Jul; 18(14):1833-48. PubMed ID: 10407255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive group sequential survival comparisons based on log-rank and pointwise test statistics.
    Feld J; Faldum A; Schmidt R
    Stat Methods Med Res; 2021 Dec; 30(12):2562-2581. PubMed ID: 34641702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.